James Barry Sells 623 Shares of Bio-Rad Laboratories, Inc. (NYSE:BIO) Stock

Bio-Rad Laboratories, Inc. (NYSE:BIO - Get Free Report) EVP James Barry sold 623 shares of the business's stock in a transaction dated Wednesday, September 4th. The shares were sold at an average price of $330.49, for a total value of $205,895.27. Following the completion of the sale, the executive vice president now owns 147 shares in the company, valued at $48,582.03. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link.

Bio-Rad Laboratories Price Performance

Shares of NYSE:BIO traded down $3.66 during trading on Wednesday, hitting $330.65. 234,548 shares of the company were exchanged, compared to its average volume of 226,630. The business's 50 day moving average is $311.10 and its 200-day moving average is $308.14. Bio-Rad Laboratories, Inc. has a 1-year low of $261.59 and a 1-year high of $394.51. The company has a quick ratio of 4.63, a current ratio of 6.28 and a debt-to-equity ratio of 0.18. The company has a market capitalization of $9.43 billion, a P/E ratio of -31.92 and a beta of 0.93.

Bio-Rad Laboratories (NYSE:BIO - Get Free Report) last issued its earnings results on Thursday, August 1st. The medical research company reported $3.11 EPS for the quarter, beating analysts' consensus estimates of $2.12 by $0.99. Bio-Rad Laboratories had a positive return on equity of 3.77% and a negative net margin of 51.73%. The business had revenue of $638.50 million during the quarter, compared to analyst estimates of $645.79 million. During the same period in the previous year, the company posted $3.00 EPS. The firm's revenue was down 6.3% compared to the same quarter last year. Equities analysts forecast that Bio-Rad Laboratories, Inc. will post 10.31 earnings per share for the current year.

Institutional Investors Weigh In On Bio-Rad Laboratories

Large investors have recently added to or reduced their stakes in the company. Capital Advisors Ltd. LLC raised its holdings in shares of Bio-Rad Laboratories by 193.8% in the 2nd quarter. Capital Advisors Ltd. LLC now owns 94 shares of the medical research company's stock valued at $26,000 after acquiring an additional 62 shares in the last quarter. Sound Income Strategies LLC purchased a new stake in shares of Bio-Rad Laboratories in the 1st quarter valued at $38,000. Gladius Capital Management LP grew its holdings in shares of Bio-Rad Laboratories by 65.8% during the 4th quarter. Gladius Capital Management LP now owns 121 shares of the medical research company's stock valued at $39,000 after purchasing an additional 48 shares during the last quarter. Principal Securities Inc. bought a new stake in shares of Bio-Rad Laboratories in the 4th quarter valued at about $41,000. Finally, EntryPoint Capital LLC purchased a new stake in Bio-Rad Laboratories during the 1st quarter valued at about $51,000. Hedge funds and other institutional investors own 65.24% of the company's stock.

Analyst Upgrades and Downgrades

A number of brokerages recently issued reports on BIO. Royal Bank of Canada reissued an "outperform" rating and issued a $401.00 target price on shares of Bio-Rad Laboratories in a research report on Friday, August 16th. UBS Group lowered their price objective on shares of Bio-Rad Laboratories from $420.00 to $385.00 and set a "buy" rating on the stock in a report on Wednesday, May 8th. Citigroup upped their target price on Bio-Rad Laboratories from $300.00 to $350.00 and gave the stock a "neutral" rating in a report on Friday, August 2nd. StockNews.com lowered shares of Bio-Rad Laboratories from a "buy" rating to a "hold" rating in a research report on Thursday, August 1st. Finally, Wells Fargo & Company began coverage on Bio-Rad Laboratories in a research note on Tuesday, August 27th. They set an "equal weight" rating and a $340.00 target price for the company. Four research analysts have rated the stock with a hold rating and two have assigned a buy rating to the company. According to data from MarketBeat, the stock has an average rating of "Hold" and a consensus price target of $358.20.

Bio-Rad Laboratories Company Profile

Bio-Rad Laboratories, Inc manufactures and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. It operates through two segments, Life Science and Clinical Diagnostics. The company develops, manufactures, and markets instruments, systems, reagents, and consumables to separate, purify, characterize, and quantitate biological materials such as cells, proteins, and nucleic acids for proteomics, genomics, biopharmaceutical production, cellular biology, and food safety markets.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.